title: Systemic lupus erythematosus with acanthosis nigricans, hyperpigmentation, and insulin receptor antibody.
abstract: Acanthosis nigricans, insulin receptor antibody, and systemic lupus erythematosus are associated in the potentially lethal syndrome of type B insulin resistance. Hyperpigmentation has been reported rarely, while glucose intolerance is common in these patients. We report an adolescent girl with acanthosis nigricans, hyperpigmentation, insulin receptor antibody, and systemic lupus erythematosus without glucose intolerance. Insulin resistance may be mild or transient in some patients with type B insulin resistance. Resolution of skin lesions was noted during therapy of SLE, and was associated with disappearance of insulin receptor antibody.
authors.affiliation: New York Hospital/Cornell Medical Center, New York, USA.
authors.forename: J S
authors.initials: JS
authors.lastname: Baird
authors.forename: J L
authors.initials: JL
authors.lastname: Johnson
authors.forename: D
authors.initials: D
authors.lastname: Elliott-Mills
authors.forename: L M
authors.initials: LM
authors.lastname: Opas
mesh_terms: D000052:Acanthosis Nigricans / Q000188:drug therapy / Q000209:etiology*; D000293:Adolescent; D000918:Antibody Specificity; D001323:Autoantibodies / Q000097:blood / Q000276:immunology*; D001327:Autoimmune Diseases / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D017495:Hyperpigmentation / Q000188:drug therapy / Q000209:etiology; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007333:Insulin Resistance; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D011972:Receptor, Insulin / Q000276:immunology*
chemical_list: D001323:Autoantibodies; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D011972:Receptor, Insulin